EFE. V. Fedotova

E. V. Fedotova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


E. V. Fedotova has a total of 13 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Honey-based hydrogel: A promising new-generation antimicrobial coating?

    by E. N. Karpina, E. V. Fedotova, F. F. Zaripova, D. V. Krivorotov, A. S. Radilov

    Introduction. The development of hydrogel coatings is a promising research direction in burn injury therapy. Honey-based hydrogels possess unique physicochemical characteristics due to being transparent, capable of effectively absorbing exudate, and exhibiting low pH values. All these properties make them ideal candidates for application not only in cosmetology but also in medicine for the transdermal delivery of various medicinal substances. Objective. Synthesis of honey-based hydrogels and comparative analysis of their physicochemical characteristics and antibacterial activity. Materials and methods. Hydrogels were synthesized based on chitosan and сarbopol with addition of 25, 50, and 75 wt % of white honey. The following parameters were investigated: viscosity (using a Brookfield rotational viscometer); spreadability (by a compression method); degree of sample swelling; stability (by centrifugation); honey release from the sample (using an ERWEKA DT-820 tester); analysis of the quantitative honey content in the buffer (by spectrophotometry). The study of in vitro antibacterial properties was conducted using Candida  albicans ATCC 64550 (a yeast-like fungus), Staphylococcus aureus ATCC 25913 (a gram-positive bacterium), Escherichia coli ATCC 25922 (a gram-negative bacterium), Acinetobacter baumannii 897 (a gram-negative bacterium), Enterobacter cloacae ATCC 13047 (a gram-negative bacterium), Klebsiella pneumoniae ATCC 19606 (a gram-negative bacterium). Statistical data processing was performed using the DeltaX 3.0 software. Results. In terms of viscosity, the hydrogel based on 1% Carbopol 940 with a honey concentration of 25 wt % outperformed other gels. The samples based on 1% Carbopol ETD 2020 with a honey concentration of 50 wt % exhibited the lowest spreadability. The highest sorption capacity 1 h and 3 h after the onset of testing was demonstrated by the sample based on 3.5% low-viscosity chitosan with a honey concentration of 25 wt %. The highest honey release was shown by the sample based on 10% low-viscosity chitosan with a honey concentration of 50 wt %. Conclusions. The conducted study of physicochemical and antibacterial properties render chitosan-based hydrogels promising for further investigation. Hydrogel samples with a 75% honey concentration failed the stability test, which make them unsuitable for use as a therapeutic delivery system. Based on the results obtained, a mixed hydrogel based on Carbopol 940 and 3.5% low-viscosity chitosan is recommended for further research.

  • Open Access

    Soy lecithin-based liposomes for lymphatic delivery of biologically active substances

    by E. V. Fedotova, N. V. Skvortsov, I. E. Perevoznikov, N. Yu. Rogovskaya, A. A. Bardin, P. P. Beltyukov, V. N. Babakov, D. V. Krivorotov, A. S. Radilov, Н. Ю. Роговская

    Липосомы из соевого лецитина для лимфатической доставки биологически активных веществ

  • Open Access

    Prospects for the use of intranasal nanoscale polymer delivery systems for drugs and antidotes in extreme medicine

    by E. V. Fedotova, D. V. Krivorotov, A. S. Radilov

    Introduction. The development of improved formulations of antidotes and remedies, which can be used not only by qualified medical personnel, but also in self- and mutual assistance, is an urgent task for extreme medicine.Objective. Evaluation of the possibility of using nanoscale polymer delivery systems for medicines and antidotes intended for intranasal administration (into the nasal cavity) in extreme medicine.Discussion. The main submicron-sized polymer carriers which are promising as the basis for the creation of an intranasal form of antidotes are identified. The bioavailability of the substance delivered is dependent on the physico-chemical properties of the carrier, the conditions for its production, as well as physiological and anatomical factors. Data is presented regarding possible ways of correcting these factors in order to increase bioavailability. Examples of the use of polymer nanocarriers in the treatment of poisoning with heavy metals and rocket fuel components, as well as lesions caused by radioactive substances, are presented. It is shown that carriers (dendrimers, cyclodextrins) can act as antidotes in certain cases. The study presents a list of antidotes approved for use within the territory of the Russian Federation, for which the development of intranasal forms is possible, taking their physico-chemical and pharmacokinetic properties into account.Conclusions. Following a review of literature sources, the most promising submicron-sized polymer carriers for the intensification of intranasal delivery of drugs and antidotes are herein proposed: dendrimers, liposomes, nanocapsules, nanoparticles, and cyclodextrins. Using the list of antidotes approved for use in the Russian Federation as an example, promising drugs that can be potentially developed on the basis of these carriers are proposed.

  • PAMAM dendrimers and prospects of their application in medicine

    by Ev Popova, Dv Krivorotov, Rv Gamazkov, As Radilov

    Development of drug delivery systems based on branched biocompatible polymers is one of the most promising areas of modern nanopharmaceutics. Researchers have been exploring this area several decades now, and the results of their efforts quickly find their way into production. Dendrimers, a new class of universal synthetic polymers with a highly functional surface, have a number of unique properties: constant size, high degree of branching, multivalence, solubility in water, definite molecular weight, internal cavities. With the release of VivaSol gel, the first dendrimer-based commercialized product, the "model range" of dendrimer carriers has grown significantly. Poly(amide-amine) (PAMAM) dendrimers, which consist of an alkyldiamine core and tertiary amine branches, are believed to be among the most promising compounds that can be used in the development of the new generation drugs. However, they were kept out of the list of clinically acceptable compounds for a long time because of their toxicity, unclear behavior in living systems and pharmacokinetic profile, as well the difficulties associated with establishing a therapeutic dose. This review presents basic information about PAMAM dendrimers and attempts to assess the prospects of their application in treatment of various diseases, including COVID-19.